Ahmad Haidar, MD
Internal Medicine · Carriere, MSNPI 1407837503
Payments from drug & device makers
Across 240 payments — averaging $24.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$980
- AstraZeneca$957
- Sunovion Pharmaceuticals Inc.$350
- Novo Nordisk$339
- GSK$326
- Lundbeck LLC$312
- plus $3K from 30 others
What the payments were for
- Food & beverage$5,66897%
- Education$2013%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 42 | $980 |
| AstraZeneca | 21 | $957 |
| Sunovion Pharmaceuticals Inc. | 25 | $350 |
| Novo Nordisk | 8 | $339 |
| GSK | 18 | $326 |
| Lundbeck LLC | 19 | $312 |
| Astellas Pharma US Inc | 6 | $260 |
| Johnson & Johnson | 3 | $246 |
| Lilly USA, LLC | 13 | $233 |
| Pfizer | 11 | $204 |
| Avanir Pharmaceuticals, Inc. | 13 | $194 |
| Amgen | 6 | $187 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $166 |
| Biogen | 7 | $139 |
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $100 |
| Bayer | 6 | $92 |
| Paratek Pharmaceuticals, Inc. | 4 | $83 |
| CSL Behring | 2 | $83 |
| Axsome Therapeutics, Inc. | 3 | $80 |
| Vanda Pharmaceuticals Inc. | 2 | $45 |
| Boehringer Ingelheim | 1 | $44 |
| Corium, LLC | 2 | $41 |
| Idorsia Pharmaceuticals US Inc | 2 | $33 |
| Supernus Pharmaceuticals, Inc. | 2 | $31 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Otsuka America Pharmaceutical, Inc. | 2 | $28 |
| Novartis | 1 | $23 |
| Philips North America LLC | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Abbott | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Indivior Inc. | 1 | $17 |
| Mylan Specialty L.p. | 1 | $16 |
| Shire North American Group Inc | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,869 in reported general payments places this provider in the 90th percentile of 846 internal medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 298 | $318,628 |
| EliquisApixaban | 621 | $236,955 |
| JardianceEmpagliflozin | 251 | $139,700 |
| MounjaroTirzepatide | 85 | $99,583 |
| AustedoDeutetrabenazine | 25 | $90,299 |
| FarxigaDapagliflozin Propanediol | 94 | $57,417 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 78 | $54,720 |
| NuedextaDextromethorphan Hbr/Quinidine | 79 | $52,423 |
| JanuviaSitagliptin Phosphate | 106 | $48,215 |
| MyrbetriqMirabegron | 150 | $42,954 |
| VraylarCariprazine Hcl | 50 | $35,486 |
| LinzessLinaclotide | 44 | $31,054 |
| TrulicityDulaglutide | 33 | $29,892 |
| EntrestoSacubitril/Valsartan | 49 | $26,218 |
| XareltoRivaroxaban | 69 | $25,361 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Levemir | $339 | $347,211353 claims |
| PfizerEliquis, Premarin | $204 | $243,464633 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $44 | $163,916318 claims |
| Lilly USA, LLCMounjaro, Trulicity | $233 | $129,475118 claims |
| AbbVieVraylar, Linzess, Restasis | $980 | $77,957111 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $957 | $76,865116 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $326 | $73,028118 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $194 | $52,42379 claims |
| Astellas Pharma US IncMyrbetriq | $260 | $42,954150 claims |
| Johnson & JohnsonXarelto, Invokana | $246 | $38,64999 claims |
| NovartisEntresto | $23 | $26,21849 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $28 | $12,46111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 846 internal medicine providers in Mississippi.
Other internal medicine in Carriere
- James HallBrookhaven$4.8M
- Bob HutchinsJackson$4.6M
- Sidney GortonBelzoni$571K
- David PendleyGulfport$336K
- Sarah KerutJackson$319K
- Gabriel HernandezJackson$196K
- Kelly WilkinsonJackson$183K
- Magdy Gorgi-MikhailBiloxi$157K
- Christina BarlowJackson$129K
- Arnold JacksonHattiesburg$121K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.